Seroatlas · Human Serome Atlas

YIPF2

Protein YIPF2

Also known as: FinGER2, MGC3262, YIPF2_HUMAN

Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene

Protein identityUniProt · HPA

UniProt accession: Q9BWQ6
Gene: YIPF2
Ensembl: ENSG00000130733
Chromosome: 19
Canonical length: 316 aa
Protein class: Predicted intracellular proteins, Predicted membrane proteins, Transporters
Subcellular location: Golgi apparatus,Mitochondria

OverviewNCBI Gene

Predicted to enable small GTPase binding activity. Predicted to be involved in vesicle-mediated transport. Located in Golgi apparatus subcompartment and transport vesicle. [provided by Alliance of Genome Resources, Jul 2025]

Canonical amino-acid sequenceUniProt

316 residues, UniProt reviewed canonical sequence.

>Q9BWQ6|YIPF2
     1  MASADELTFH EFEEATNLLA DTPDAATTSR SDQLTPQGHV AVAVGSGGSY GAEDEVEEES
    61  DKAALLQEQQ QQQQPGFWTF SYYQSFFDVD TSQVLDRIKG SLLPRPGHNF VRHHLRNRPD
   121  LYGPFWICAT LAFVLAVTGN LTLVLAQRRD PSIHYSPQFH KVTVAGISIY CYAWLVPLAL
   181  WGFLRWRKGV QERMGPYTFL ETVCIYGYSL FVFIPMVVLW LIPVPWLQWL FGALALGLSA
   241  AGLVFTLWPV VREDTRLVAT VLLSVVVLLH ALLAMGCKLY FFQSLPPENV APPPQITSLP
   301  SNIALSPTLP QSLAPS

LocalizationUniProt · AlphaFold · HPA

Whether an antibody against YIPF2 can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.

Antibody reachability: Other membrane
Secreted: No
Transmembrane segments: 5
Mean surface accessibility (rSASA): 0.41
Highest tissue expression: 108 nTPM

Expression across tissuesHPA

Tissue

pancreas: 108 nTPM
pituitary gland: 103 nTPM
salivary gland: 99 nTPM
testis: 73 nTPM
liver: 52 nTPM
esophagus: 48 nTPM

Single-cell type

late primary spermatocytes: 280 nCPM
syncytiotrophoblasts: 250 nCPM
extravillous trophoblasts: 169 nCPM
esophageal apical cells: 161 nCPM
epididymal principal cells: 157 nCPM
cytotrophoblasts: 139 nCPM

Immune cell

basophil: 39 nTPM
plasmacytoid DC: 34 nTPM
myeloid DC: 22 nTPM
intermediate monocyte: 21 nTPM
non-classical monocyte: 20 nTPM
classical monocyte: 19 nTPM

Brain region

choroid plexus: 56 nTPM
medulla oblongata: 38 nTPM
pons: 35 nTPM
cerebellum: 34 nTPM
hypothalamus: 34 nTPM
midbrain: 33 nTPM

Genetic constraint and essentialitygnomAD · DepMap

Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.

gnomAD LOEUF (loss-of-function intolerance): 1.28
gnomAD pLI: 0
gnomAD missense Z: -0.14
DepMap mean gene effect: -0.19
DepMap dependency class: selective

Cancer expressionTCGA

Across TCGA tumor cohorts, this protein is over-expressed in roughly 6% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).

OntologyGO

Biological processes

vesicle-mediated transport

Molecular functions

small GTPase binding

Cellular components

Protein domainsUniProt · Pfam · InterPro

KeywordsUniProt

InteractionsUniProt · HPA

Protein binding partners of YIPF2 in the human serome: UniProt-annotated complex subunits plus reported interactors. Each links to its own Seroatlas record.

Antibody and autoantibody relevanceSeroatlas analysis

Seroatlas reads YIPF2 as an antibody target. Whether an autoantibody or antibody against YIPF2 could matter depends on whether native YIPF2 is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.

YIPF2 is annotated as predominantly intracellular. Intracellular proteins are common autoantibody markers, becoming visible to the immune system after cell injury or altered processing, but are usually markers of disease rather than direct drivers.

Annotation status

The present source text does not explicitly label YIPF2 as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.

Loading the interactive Seroatlas protein explorer...